PENCAPAIAN TEKANAN INTRAOKULAR PASCA PEMBERIAN TIMOLOL MALEAT 0,5% PADA GLAUKOMA SUDUT TERBUKA PRIMER DI POLIKLINIK MATA RSUP PROF. DR. R. D. KANDOU MANADO TAHUN 2012-2014

Authors

  • Andrea Lalita
  • Yamin Tongku
  • J. S. M. Saerang

DOI:

https://doi.org/10.35790/ecl.v4i1.10969

Abstract

Abstract: Primary Open Angle Glaucoma (POAG) is the most often type of glaucoma. Glaucoma is one of the most common cause of irreversible blindness worldwide, whereas POAG has nearly 90% of all types of glaucoma. Timolol maleate 0.5% is a non-selective beta adrenergic receptor inhibitor commonly used in the POAG treatment. Mechanism of action of this drug is lowering or suppressing the aquous humor production. The level of intraocular pressure (IOP) reduction in patients with timolol can reach a percentage of 20-30%. This was a retrospective descriptive study. Respondents were POAG patients with timolol maleate 0.5% therapy in the Department of Ophtalmology Prof. Dr. R. D. Kandou Hospital Manado. This study was conducted in November 2015. The results showed that there were 15 respondents who fulfilled the criterias. Of the 15 patients, 8 patients (54%) came for the first control (a week/a month). There were 9 female patients (60%) and 6 male patients (40%). By group of age, the highest percentage was elderly aged 51-60 years (40%). There were 11 patients (74%) with bilateral POAG and only 4 patients (26%) with unilateral POAG. The average percentage of IOP reduction among POAG patients with timolol maleate 0.5% therapy was 16.52%. Conclusion: Among POAG patients with timolol maleate 0.5% therapy there was a 16.52% decrease of the average intraocular pressure in the first control.

Keywords: primary open-angle glaucoma, timolol, intraocular pressure

 

Abstrak: Glaukoma Sudut Terbuka Primer (GSTaP) adalah tipe yang paling sering timbul dari penyakit glaukoma. Glaukoma merupakan salah satu penyebab tersering dari kebutaan yang ireversibel di seluruh dunia, dan GSTaP terdapat hampir 90% dari semua tipe penyakit glaukoma. Timolol maleat 0,5% yaitu penghambat reseptor beta adrenergik non selektif merupakan salah satu obat yang paling sering digunakan untuk pengobatan GSTaP. Mekanisme kerja obat ini ialah menurunkan atau supresi produksi humor akuous. Tingkat penurunan TIO (tekanan intraokular) pada pengguna timolol mencapai 20-30%. Penelitian ini bersifat deskriptif retrospektif. Sampel penelitian ialah pasien GSTaP dengan terapi timolol maleat 0,5% di Poliklinik Mata RSUP Prof. Dr. R. D. Kandou Manado. Penelitian ini dilakukan selama bulan November 2015 dengan jumlah sampel 15 orang yang telah memenuhi kriteria penelitian. Hasil penelitian menunjukkan dari 15 pasien tersebut, 8 pasien (54%) datang kembali untuk kontrol (1 minggu/1 bulan pertama). Yang berjenis kelamin perempuan lebih banyak yaitu 9 pasien (60%) sedangkan laki-laki hanya 6 pasien (40%). Berdasarkan kelompok umur, rata-rata umur lansia paling banyak; yang terbanyak yaitu umur 51-60 tahun (40%). Dilihat dari sisi mata, kasus bilateral lebih banyak berjumlah 11 pasien (74%) dibandingkan unilateral hanya 4 pasien (26%). Rerata persentase penurunan TIO pada pasien GSTaP dengan menggunakan terapi timolol maleat 0,5% ialah 16,52%. Simpulan: Pada pasien GSTaP yang diberikan timolol maleat 0,5% terdapat rerata penurunan TIO sebesar 16,52% pada kontrol pertama.

Kata kunci: glaukoma sudut terbuka primer, timolol, tekanan intraokular

Downloads

How to Cite

Lalita, A., Tongku, Y., & Saerang, J. S. M. (2016). PENCAPAIAN TEKANAN INTRAOKULAR PASCA PEMBERIAN TIMOLOL MALEAT 0,5% PADA GLAUKOMA SUDUT TERBUKA PRIMER DI POLIKLINIK MATA RSUP PROF. DR. R. D. KANDOU MANADO TAHUN 2012-2014. E-CliniC, 4(1). https://doi.org/10.35790/ecl.v4i1.10969

Issue

Vol. 4 No. 1 (2016): Jurnal e-CliniC (eCl)

Section

Articles

License

COPYRIGHT

 

Authors who publish with this journal agree to the following terms:

Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.

Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.

Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).